8-K: Autonomix Medical Announces 1-for-21 Reverse Stock Split

Autonomix Medical is consolidating its common stock through a 1-for-21 reverse split effective June 24, 2026, to restructure its equity and maintain market compliance.

Summary

• A 1-for-21 reverse stock split will take effect at 12:01 a.m. Eastern Time on June 24, 2026.
• The total number of issued and outstanding shares of common stock will be reduced from approximately 11,409,344 to approximately 542,000.
• The number of authorized shares of common stock remains unchanged at 500,000,000.
• Net loss for the fiscal year ended March 31, 2026, was $16.715 million, compared to $11.410 million in the prior year.
• Post-split net loss per share for the 2026 fiscal year is retroactively adjusted to $48.80 per share.
• No fractional shares will be issued; stockholders entitled to fractions will receive cash payments based on the average closing price of the five preceding trading days.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a distressed move to maintain listing compliance amidst widening losses and a lack of commercialized products.

Positives

• The reverse split is intended to increase the per-share trading price, which typically helps in meeting Nasdaq minimum bid price requirements for continued listing.
• Proportionate adjustments to stock options and warrants ensure that the relative equity interests of holders remain consistent.

Negatives

• The company reported a significant net loss of $16.715 million for the year ended March 31, 2026.
• The 1-for-21 ratio is highly aggressive, often indicating a severe lack of confidence in the organic recovery of the share price.
• Maintaining 500 million authorized shares while only having 542,000 shares outstanding creates a massive overhang for potential future dilution.

Risks

• The post-split float of approximately 542,000 shares is extremely low, which may lead to excessive stock price volatility.
• There is no guarantee that the reverse split will result in a sustained increase in the stock price or satisfy long-term listing requirements.
• Ongoing losses and a lack of revenue from investigational products pose a risk to liquidity and going concern status.

Future Outlook

The company continues to develop its catheter-based microchip sensing array for transvascular diagnosis and treatment of peripheral nervous system diseases, with initial clinical focus on pancreatic cancer pain.

Management Comments

• The reverse stock split will take effect at 12:01 a.m. Eastern Time on June 24, 2026.
• Proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all outstanding stock options and warrants.

Industry Context

StockSavvy.ai notes that reverse splits are a common defensive mechanism for micro-cap medical technology companies to avoid delisting from major exchanges like Nasdaq when their share price falls below $1.00.

Comparison to Industry Standards

• The 1-for-21 ratio is significantly higher than the typical 1-for-5 or 1-for-10 ratios seen in the medical device sector, suggesting more acute price pressure.
• A post-split float of roughly 542,000 shares is exceptionally low compared to peers, placing the company in the 'ultra-low float' category which is prone to high-frequency trading volatility.

Corporate Governance

Stakeholder Impact

• Shareholders will see their total number of shares held decrease by 95.2%.
• Warrant and option holders will see their exercise prices increase by 21 times.
• The market may experience increased volatility due to the significantly reduced share float.

Next Steps

• Common stock begins trading on a post-split basis on June 24, 2026.
• The company will issue cash payments to stockholders who would have held fractional shares.

Key Dates

Recommendation

The combination of widening net losses, an aggressive 1-for-21 split ratio, and the decision to keep authorized shares at 500 million suggests a high probability of future dilutive capital raises and fundamental instability.

Keywords

Reverse Stock Split, Autonomix Medical, AMIX, Medical Device, Nasdaq Compliance, Capital Restructuring, Nerve-Targeted Treatment